Tryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail GrowthNuminus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company LabWill The ATAI Life Sciences IPO Bring Investor Interest Back To the Psychedelics Sector?MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During PCybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and AddictionTryp Therapeutics Reports on Key Milestones for 2021Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (

Technical420 Site Search

Returned 93 result(s).

MushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)

Over the past year there has been a significant increase in interest in companies that are focused on the psychedelic therapy market--a trend that we are following closely. Interest in these companies has been steadily rising in 2021, and we are focused on identifying businesses that have staying power. Tryp…

GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug…

Cardiol Therapeutics’ Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer of its pure pharmaceutical CBD, was selected to…

Premier Health Group Has Been Red Hot On The Acquisition Trail

2019 has been a banner year for Premier Health Group Inc. (PHGI.CN) (PHGRF) and this is an opportunity that we have been closely watching. Earlier this year, the company completed the acquisition of Cloud Practice and we believe that this was a transformational acquisition for Premier Health. This acquisition has…

Cardiol Is Leveraging Cutting Edge Technologies To Bring Game-Changing Products To Market

In late 2018, Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) commenced trading on the Toronto Stock Exchange (TSX) and we have been closely following the Canadian biotech company. We believe that the biotech industry will be one of the greatest beneficiaries of the legal cannabis movement and for this reason, investor…

Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon

Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave") and Intrexon Corporation (NASDAQ: XON) ("Intrexon") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars…

Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001

Tetra Bio-Pharma Inc. today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as…

IntelGenx Signs Letter of Intent with Tilray® to Enter Into a World-Wide Agreement To Produce Cannabis-Infused VersaFilm™ Products

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) today announced that it has executed a non-binding letter of intent (the “LOI”) with Tilray, Inc. (https://www.globenewswire.com/Tracker...) (NASDAQ:TLRY) (“Tilray(®)”), a global leader in cannabis research, cultivation, production and distribution, to co-develop and commercialize oral film products infused with recreational and medical cannabis (“cannabis-infused VersaFilm™”), in…

InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced that is has received final approval for the listing of the Company's common shares (the "Common Shares") on the Toronto Stock Exchange (the "TSX"). The Common Shares…

InMed Receives Conditional Approval to List on the Toronto Stock Exchange

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to list its common shares ("Common Shares") on the TSX.  Final approval…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link